The Endocannabinoidome: Why the Endocannabinoid System Is Far Bigger Than Anyone Thought
New approaches and challenges to targeting the endocannabinoid system.
The 'endocannabinoid system' is actually part of a much larger network — the endocannabinoidome — with 20+ receptors and dozens of signaling molecules, which explains why CBD works, why single-target drugs fail, and why cannabis affects so many systems.
For twenty years, the endocannabinoid system had a clean story. Two receptors: CB1 in the brain, CB2 in the immune system. Two signaling molecules: anandamide and 2-AG. A handful of enzymes to build and break them down. It fit on a textbook page. It was elegant. It was teachable.
It was also incomplete.
By 2018, the evidence had accumulated to the point where one of the field's most influential researchers felt compelled to redraw the map entirely. Vincenzo Di Marzo — the Italian-born chemist who had spent decades studying endocannabinoid metabolism — published a landmark review in Nature Reviews Drug Discovery, the world's highest-ranked drug discovery journal, arguing that the "endocannabinoid system" was actually part of something much larger.
He called it the endocannabinoidome.
The Problem With the Old Map
The classical ECS model worked beautifully — until it didn't. As researchers tried to develop drugs based on the two-receptor, two-molecule model, they kept running into problems that the map couldn't explain.
The pattern was telling. Drugs designed to precisely target CB1 or CB2 kept producing unexpected effects — suggesting they were hitting parts of a system nobody had mapped. Meanwhile, CBD was working clinically despite the classical model saying it shouldn't, because it barely interacts with CB1 or CB2.
Something was missing from the picture.
The Endocannabinoidome
Di Marzo's answer was that the endocannabinoid system isn't a system at all — it's a subsystem, embedded within a much larger network of lipid signaling molecules, receptors, and enzymes.
The term "endocannabinoidome" captured a simple but powerful idea: the molecules we call endocannabinoids don't operate in isolation. They're part of a family of lipid mediators — chemically related fatty molecules — that interact with a constellation of receptors far beyond CB1 and CB2. And these interactions aren't peripheral curiosities. They're central to how the system actually works.
Why This Explains CBD
Myth vs. Reality
CBD doesn't work because it doesn't bind to cannabinoid receptors.
CBD barely binds to CB1 or CB2 — the two 'cannabinoid receptors.' But the endocannabinoidome includes over 20 receptors that respond to cannabinoids and related molecules. CBD interacts with several of them: it activates TRPV1 (involved in pain perception), modulates GPR55 (involved in bone density and cancer cell proliferation), engages PPARγ (involved in inflammation), and inhibits FAAH (the enzyme that breaks down anandamide, effectively boosting your body's own endocannabinoid levels). CBD works — it just doesn't work through the receptors the textbook focused on.
The Evidence
CBD's clinical efficacy is established: FDA-approved for epilepsy (Epidiolex), with evidence in anxiety, psychosis, and inflammation. Its receptor profile includes TRPV1, 5-HT1A, GPR55, PPARγ, and FAAH modulation — all endocannabinoidome targets.
Di Marzo (2018), Nat Rev Drug Discov; Devinsky et al. (2017), NEJM
This was perhaps the most practically significant implication of the endocannabinoidome concept. For years, CBD skeptics had argued that it couldn't work because it doesn't bind CB1 or CB2. The endocannabinoidome showed that this argument was based on an incomplete map. CBD doesn't need CB1 or CB2 — it has an entire network of alternative targets.
It also explains why full-spectrum cannabis products sometimes produce different effects than isolated THC. When you consume whole-plant cannabis, dozens of compounds are interacting with the endocannabinoidome simultaneously — a fundamentally different pharmacological event than flooding CB1 with pure THC.
The Man Who Redrew the Map
Vincenzo Di Marzo trained as an organic chemist in Naples and spent decades at the Italian National Research Council (CNR) studying how endocannabinoids are made and broken down in cells. His lab was instrumental in characterizing the enzymes that synthesize and degrade 2-AG — the more abundant of the two classical endocannabinoids.
But Di Marzo was never satisfied with the clean two-receptor model. As his lab and others discovered more lipid mediators that interacted with cannabinoid-related receptors, and more receptors that responded to cannabinoid-like molecules, the boundary of the "endocannabinoid system" kept expanding. At some point, he realized the boundary was artificial — what existed wasn't a small system with neat borders but a large, interconnected network of lipid signaling that the field had been studying one piece at a time.
He coined the term "endocannabinoidome" to name what he was seeing. By 2018, the concept had matured enough — and the clinical failures had accumulated enough — for him to make the case in the field's most prominent review venue.
What Failed and Why
The endocannabinoidome concept doesn't just explain CBD. It explains the failures.
The Gut Connection
One of the most surprising aspects of the endocannabinoidome was its connection to the gut microbiome. Di Marzo highlighted emerging evidence that gut bacteria produce and respond to endocannabinoidome mediators — creating a signaling axis between the microbiome, the endocannabinoidome, and the brain.
This gut-endocannabinoidome-brain axis is now an active area of research, with implications for metabolic disease, mood disorders, and inflammatory conditions. It suggests that some of the effects of cannabis on appetite, nausea, and gut function may operate through this pathway rather than through direct CB1 activation in the brain.
What It Means Going Forward
2 → 20+
The number of receptors in the endocannabinoid system expanded tenfold when Di Marzo redrew the map. The classical model of 2 receptors, 2 endocannabinoids, and 5 enzymes gave way to a network of 20+ receptors, 12+ mediators, and dozens of enzymes — the endocannabinoidome.
This is comparable to discovering that the solar system, which you thought had 9 planets, actually has hundreds of objects worth studying. The original planets are still there — they're just part of something much bigger.
Di Marzo (2018), Nat Rev Drug Discov 17:623-639
The endocannabinoidome doesn't invalidate what we knew about the ECS — it extends it. CB1 and CB2 are still real and important. Anandamide and 2-AG are still the primary endocannabinoids. But they operate within a context that's far richer and more interconnected than the textbook version suggests.
For drug development, this means shifting from single-target precision drugs to strategies that work with the network — or, as Di Marzo noted, learning from botanical preparations like CBD that already engage multiple targets naturally.
For cannabis users, it means that the entourage effect has a plausible biological mechanism. When terpenes, minor cannabinoids, and CBD interact with a 20+ receptor network alongside THC, the pharmacological outcome is genuinely different from THC alone.
Frequently Asked Questions
Cite this study
Di Marzo, Vincenzo. (2018). New approaches and challenges to targeting the endocannabinoid system.. Nature reviews. Drug discovery, 17(9), 623-639. https://doi.org/10.1038/nrd.2018.115